Peak Bio Analyst Ratings
Peak Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/04/2022 | 294.74% | Ladenburg Thalmann | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 4 月 11 日 | 294.74% | 拉登堡塔爾曼 | → 15 美元 | 啓動保障 | → 購買 |
Peak Bio Questions & Answers
Peak Bio 問題與解答
The latest price target for Peak Bio (NASDAQ: PKBO) was reported by Ladenburg Thalmann on November 4, 2022. The analyst firm set a price target for $15.00 expecting PKBO to rise to within 12 months (a possible 294.74% upside). 1 analyst firms have reported ratings in the last year.
拉登堡·塔爾曼於2022年11月4日公佈了匹克生物（納斯達克股票代碼：PKBO）的最新目標股價。該分析公司將目標股價設定爲15.00美元，預計PKBO將在12個月內上漲至15.00美元（可能上漲294.74％）。去年有1家分析公司公佈了評級。
The latest analyst rating for Peak Bio (NASDAQ: PKBO) was provided by Ladenburg Thalmann, and Peak Bio initiated their buy rating.
匹克生物（納斯達克股票代碼：PKBO）的最新分析師評級由拉登堡·塔爾曼提供，匹克生物啓動了買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Peak Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Peak Bio was filed on November 4, 2022 so you should expect the next rating to be made available sometime around November 4, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Peak Bio的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Peak Bio的最後一次評級是在2022年11月4日提交的，因此您應該預計下一個評級將在2023年11月4日左右公佈。
While ratings are subjective and will change, the latest Peak Bio (PKBO) rating was a initiated with a price target of $0.00 to $15.00. The current price Peak Bio (PKBO) is trading at is $3.80, which is within the analyst's predicted range.
儘管評級是主觀的，而且將發生變化，但最新的Peak Bio（PKBO）評級是啓動的，目標股價爲0.00美元至15.00美元。Peak Bio（PKBO）目前的交易價格爲3.80美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。